Adults with heart disease who started the cholesterol injection Repatha had a 20% lower rate of heart attacks than similar patients who started the pill ezetimibe, in a study of 544,103 U.S. patients published in the American Journal of Preventive Cardiology. The hazard ratio for fatal or nonfatal heart attack was 0.80, according to an Amgen announcement Nov. 5.
In absolute terms, the difference was smaller. Among patients with a recorded starting LDL cholesterol level, the estimated four-year risk of heart attack was 5.88% with Repatha and 7.76% with ezetimibe, a gap of about 1.9 percentage points.